PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 767 (118th)

Protecting Access to Medication Abortion Act of 2023

referredUnited States· United States Congress· EN

Introduced

2 February 2023

Last action

10 February 2023 · Referred

Status

Referred to the Subcommittee on Health.

Sponsors

Cori Bush, Rep. Omar, Ilhan [D-MN-5], Darren Soto, Sheila Jackson Lee, Betty McCollum, Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Beyer, Donald S. [D-VA-8], Rep. Carson, André [D-IN-7], Gwen Moore, Rep. Pingree, Chellie [D-ME-1], Rep. Lieu, Ted [D-CA-36], Rep. Casar, Greg [D-TX-35], Rep. Scanlon, Mary Gay [D-PA-5], Sen. Schiff, Adam B. [D-CA], Becca Balint, Jamaal Bowman, Rep. Barragán, Nanette Diaz [D-CA-44], Jill Tokuda, Rep. Pressley, Ayanna [D-MA-7], Rep. Ross, Deborah K. [D-NC-2], Jesús García, Donald Payne, Sydney Kamlager-Dove, Rep. Mullin, Kevin [D-CA-15], Jahana Hayes, Mary Peltola, Rep. Goldman, Daniel S. [D-NY-10], Rep. Cohen, Steve [D-TN-9], Rep. Lee, Susie [D-NV-3], Dean Phillips, Rep. Salinas, Andrea [D-OR-6]

Subjects

Healthcare

Source updated

5 December 2025

Healthcare

Summary

Protecting Access to Medication Abortion Act of 2023 This bill requires the Food and Drug Administration (FDA) to ensure that patients may receive mifepristone through prescriptions issued via telehealth and filled by mail. The FDA has approved mifepristone for medication abortions (i.e., a procedure in which prescription drugs are used to terminate a pregnancy). (Mifepristone is subject to a Risk Evaluation and Mitigation Strategy, which imposes various safety-related requirements. During the COVID-19 public health emergency, the FDA suspended enforcement of a requirement that the drug must be dispensed in person, a requirement in the strategy at the time. In January 2023, the FDA updated the strategy to remove the in-person dispensing requirement.) Under this bill, the FDA must ensure that the strategy for mifepristone (1) does not have an in-person dispensing requirement, (2) allows patients to access prescriptions for mifepristone via telehealth, and (3) authorizes all pharmacies certified to dispense mifepristone to patients to do so via mail.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 2 February 2023

    Introduced

    Referred to the House Committee on Energy and Commerce.

    Source: IntroReferral

  2. 2 February 2023

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 2 February 2023

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 10 February 2023

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

Sponsors

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.